CNTB vs IMMX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IMMX Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immix Biopharma, Inc. Common Stock (IMMX) driven by superior Growth & Margin, Momentum & Technical while CNTB counters with relative strength in Valuation, Options & Structure. Fundamentally, CNTB trades at 0.8x Forward P/E with -2384.5% operating margin (+5666.7% YoY revenue) versus IMMX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CNTB sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against IMMX sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CNTB | IMMX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $42.6M | $657.1M | Larger Scale | IMMX |
| Trailing P/E Ratio Valuation | 0.8x | N/M | Lower Multiple | CNTB |
| Forward P/E Ratio Valuation | 0.8x | N/M | Lower Multiple | CNTB |
| Revenue Growth (YoY) Growth | +5666.7% | +0.0% | Higher Growth | CNTB |
| Operating Margin (TTM) Profitability | -2384.5% | 0.0% | Higher Margin | IMMX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -140.5% | -27.0% | Higher ROE | IMMX |
| 52-Week Range Position Momentum | 1% ($1โ$4) | 32% ($4โ$15) | Stronger Trend | IMMX |
| Beta / 30D Volatility Risk Regime | 0.92ฮฒ ยท 68% Vol | 1.83ฮฒ ยท 83% Vol | Lower Realized Risk | CNTB |
| Unified Institutional Score Composite Signal | 41.0 / 100 (SELL) | 53.1 / 100 (HOLD) | Higher Composite | IMMX |